Cargando…

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD

BACKGROUND: The safety and efficacy of fixed-dose combination (FDC) of glycopyrronium bromide 12.5 mg/formoterol fumarate 12 mg (GB/FF) twice daily as dry powder inhalers (DPIs) compared to glycopyrronium 50 mg monotherapy (GLY) once daily as DPI in subjects with moderate-to-severe chronic obstructi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salvi, Sundeep, Jain, Manish K., Krishnamurthy, Srikanth, Balki, Akash, Kodgule, Rahul, Tandon, Monika, Bhagat, Sagar, Panchal, Sagar, Khatri, Nishtha, Wu, Wen, Pendse, Amol, Patil, Saiprasad, Barkate, Hanmant
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746267/ https://www.ncbi.nlm.nih.gov/pubmed/36629230 http://dx.doi.org/10.4103/lungindia.lungindia_136_22

Ejemplares similares

Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
por: Salvi, Sundeep, et al.
Publicado: (2021)

Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts’ review
por: Dhar, Raja, et al.
Publicado: (2022)

Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Guo, Min, et al.
Publicado: (2022)

Retracted: The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
por: Mantero, Marco, et al.
Publicado: (2018)

Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India
por: Vaswani, Bharat, et al.
Publicado: (2020)

ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts
por: Dhar, Raja, et al.
Publicado: (2022)

Multiple analytical methods for determination of formoterol and glycopyrronium simultaneously in their novel combined metered dose inhaler
por: Salem, Yomna A., et al.
Publicado: (2019)

Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy
por: Dhungana, Santosh, et al.
Publicado: (2017)

Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma
por: Kuna, Piotr, et al.
Publicado: (2022)

The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting
por: Vaswani, Bharat, et al.
Publicado: (2021)

Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
por: Singh, Dave, et al.
Publicado: (2017)

COPD and glycopyrronium responsiveness assessment: An appraisal
por: Bhattacharyya, Parthasarathi, et al.
Publicado: (2023)

Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
por: Reddy, Pavan Kumar, et al.
Publicado: (2022)

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
por: Muro, Shigeo, et al.
Publicado: (2019)

Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study
por: Usmani, Omar S., et al.
Publicado: (2022)

Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
por: Prakash, Anoop, et al.
Publicado: (2015)

The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study
por: Vaswani, Bharat, et al.
Publicado: (2022)

The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD
por: Dean, James, et al.
Publicado: (2020)

Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors
por: Liu, Haiying, et al.
Publicado: (2022)

Real-life therapeutic effects of beclomethasone dipropionate/formoterol fumarate/glycopyrronium combined triple therapy in patients with chronic obstructive pulmonary disease
por: Pelaia, Corrado, et al.
Publicado: (2023)

Aquagenic palmoplantar keratoderma therapeutic response to topical glycopyrronium
por: Medhus, Emily J., et al.
Publicado: (2021)

Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India
por: Joshi, Shashank, et al.
Publicado: (2022)

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
por: Shah, Dhvani, et al.
Publicado: (2018)

Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis
por: Bourdin, Arnaud, et al.
Publicado: (2021)

Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation
por: Suraya, Ratoe, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain
por: Trigueros, Juan Antonio, et al.
Publicado: (2022)

Efficacy and safety of glycopyrronium/formoterol delivered via a dry powder inhaler in patients with moderate to severe chronic obstructive pulmonary disease: Results from a multi-centre, open-label, randomised study
por: Salvi, Sundeep, et al.
Publicado: (2022)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
por: Buhl, Roland, et al.
Publicado: (2012)

Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study
por: Singh, Dave, et al.
Publicado: (2017)

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
por: Udwadia, Zarir F., et al.
Publicado: (2021)

A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients
por: Zirpe, Kapil G, et al.
Publicado: (2021)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Publicado: (2014)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
por: D’Urzo, Anthony
Publicado: (2013)

The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients
por: Sanguinetti, Claudio M
Publicado: (2014)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis
por: Pariser, David M., et al.
Publicado: (2021)

Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial
por: Singh, Dave, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vql9b1691og1u22qmf07gh6oc4